Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.56B | $6.74B | $17.77 |
| 2024 | $42.88B | $6.33B | $16.58 |
| 2023 | $42.86B | $6.00B | $15.53 |
| 2022 | $44.91B | $6.95B | $17.73 |
| 2021 | $39.21B | $7.72B | $19.61 |
Social Signal Score
Earnings
Wed, Oct 28(in 2 months)
Consensus estimate $6.40 per share
Typical surprise +2.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$6.03 vs $5.72beat
- Thu, Apr 23$5.44 vs $5.25beat
- Thu, Jan 29$6.57 vs $6.45beat
- Wed, Oct 22$5.79 vs $5.50beat
- Wed, Jul 23$5.36 vs $5.23beat
- Wed, Apr 23$5.15 vs $5.10beat
Estimates and results for TMO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from TMO's reported EPS growth of -2.4% a year over 4 years.
- EPS in 5 years
- $15.87
- Implied price
- $523.65
- Return from $588.29
- -2.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $260.35 — -55.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 23 | 28 | 33 | 38 | 43 |
|---|---|---|---|---|---|
| -12.4% | -18.4% | -15.1% | -12.3% | -9.8% | -7.5% |
| -7.4% | -13.8% | -10.3% | -7.3% | -4.7% | -2.3% |
| -2.4% | -9.1% | -5.5% | -2.3% | 0.5% | 3.0% |
| 2.6% | -4.5% | -0.6% | 2.7% | 5.6% | 8.3% |
| 7.6% | 0.2% | 4.2% | 7.7% | 10.8% | 13.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsreuters.com·5d ago·Neutral
Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost Thermo Fisher Scientific is eyeing a 15%-20% increase in its customer base in India over the next five years, betting on the growing biopharma research and manufacturing ecosystem, the head of its India unit said.
View source ↗